Eli Lilly’s weight-loss treatment, Zepbound, secured approval from both U.S. and UK regulators on Wednesday, setting the stage for a robust challenger to Novo Nordisk’s Wegovy in combating surging obesity rates. Both drugs stand out as highly effective...
Powell’s Tightrope Act: Federal Reserve Winks at Rate Hike Expectations Despite Market Blues In a classic tango between expectation and reality, the Federal Reserve’s members sprang into action on Tuesday, dampening hopes that the era of rate hikes had met...
Upwork (NASDAQ: UPWK) witnessed an impressive surge in its shares, climbing over 18% in after-hours trading subsequent to the release of its Q3 results. The company outperformed expectations, reporting an EPS of $0.21, surpassing the consensus estimate of $0.10. The...
Stocks Teeter on Edge: Investors Hold Breath for Fed’s Cue while Bond Supply Looms In a week fraught with anticipation, U.S. stocks managed to inch up, resembling a tightrope walker navigating a tricky line, as investors eagerly awaited the Federal...
Vertex Pharmaceuticals (NASDAQ:VRTX) stumbled in the third quarter, missing Wall Street’s sales predictions, primarily due to lower-than-expected demand for its older cystic fibrosis (CF) treatments. The company experienced a significant 35.4% decline in sales...
